ODX was the most commonly utilized breast cancer genomic assay in the United States recorded by the NCDB in the time period 2010–2012: from 202,075 ER+/HER2-negative/lymph node-negative breast cancer patients, 69,415 (34%) had genomic tests performed with 97% of tests being ODX. Here, ERBB2 is linked to breast carcinoma.